Alle Studien
Aktiv, aber nicht rekrutierendPHASE1, PHASE2INTERVENTIONELL

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

This study is looking at a medicine called Bosutinib for children and teenagers aged 1 to 17 who have a type of blood cancer called Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML). This includes those newly diagnosed and those whose CML hasn't responded well to previous treatments or who couldn't tolerate them. The main goals are to figure out the best dose of Bosutinib for children, see how safe it is, and check if it helps treat their CML. Researchers will also learn how the body handles the medicine. The study will involve hospitals internationally, and it's designed to gather important information to help children with this condition.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE1, PHASE2
Sponsor
Children's Oncology Group
Einschreibeziel
60
Starten
06 Jul 2020
Geschätzte Fertigstellung
01 Jul 2028

Worum geht es in dieser Studie?

This research study is about a medicine called Bosutinib, which is being tested for children and teenagers between 1 and 17 years old who have Chronic Myeloid Leukemia (CML). CML is a type of blood cancer, and 'Philadelphia chromosome-positive' means it has a specific genetic change. The study involves two main groups: those recently diagnosed with CML, and those whose CML has either not responded well to other treatments (called 'resistant') or who couldn't continue other treatments because of side effects (called 'intolerant').

The study has two phases. In the first phase, doctors will carefully increase the dose of Bosutinib to find the safest and most effective amount for children, similar to the dose that works for adults. They will also look at how children's bodies react to the medicine. The second phase will then use this recommended dose to see how well it works and how safe it is for a larger group of children with CML.

Finding new and effective treatments for children with CML is very important. This study helps move us closer to understanding if Bosutinib can be a good treatment option for this specific group of patients, particularly those who might not have responded well to other medicines in the past. The goal is to improve the health and well-being of young people living with CML.

Wichtige Erkenntnisse

  • This study is for children and teenagers (1-17) with Philadelphia chromosome-positive CML.
  • It is testing a medicine called Bosutinib.
  • It includes those newly diagnosed, or those who didn't respond to previous treatments, or couldn't tolerate them.
  • The study aims to find the right dose, safety, and effectiveness of Bosutinib in young people.
  • Regular hospital visits and tests will be part of taking part.

Wer könnte berechtigt sein?

To join the first part of this study, participants must be between 1 and 17 years old. They need to have Philadelphia chromosome-positive CML that has either not responded well to at least one previous medicine (called a TKI) or they couldn't tolerate that previous medicine due to difficult side effects. We need to be sure of the CML diagnosis using specific blood and bone marrow tests.

If you're unable to take other CML medicines because of side effects, you might still be able to join, even if those medicines were working well. The doctors will decide if your side effects were significant enough to consider you for this study.

Later in the study, participants will also include those who have recently been diagnosed with CML and haven't had other treatments yet, as well as those with more advanced stages of CML (called accelerated or blast phase), provided they also have the Philadelphia chromosome and resistance or intolerance to previous treatments.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you between 1 and 17 years old?
  2. Do you have Philadelphia chromosome-positive CML?
  3. Has your CML not responded well to previous treatments, or did you have significant side effects from them?
  4. Are you willing to have regular blood tests and bone marrow checks?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study will involve regular visits to the hospital. Doctors will perform tests, including blood tests and bone marrow checks, to monitor your CML and how you're responding to the Bosutinib. You'll take Bosutinib medicine by mouth once a day.

The study will carefully track any side effects you might experience and how the medicine works in your body. The overall length of time you'll be in the study will depend on how you respond to the treatment and your individual situation, but it will involve ongoing check-ups. The doctors and nurses will explain the full schedule of visits and assessments if you are considered for the study.

Potenzielle Risiken und Vorteile

Taking part in any study has potential benefits and risks. The potential benefit is that Bosutinib might help treat your CML, especially if other treatments haven't worked or caused too many side effects. However, there's no guarantee it will work for everyone, and like all medicines, Bosutinib can have side effects, which the medical team will monitor closely. You have the right to withdraw from the study at any time, for any reason, without affecting your future medical care.

Locations (59)

  • Children's Hospital of Alabama
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten
  • Phoenix Childrens Hospital
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten
  • Arkansas Children's Hospital
    Verifizierte Postleitzahl
    Little Rock, Vereinigte Staaten
  • Kaiser Permanente Downey Medizinisches Zentrum
    Verifizierte Postleitzahl
    Downey, Vereinigte Staaten
  • Loma Linda University Medical Center
    Verifizierte Postleitzahl
    Loma Linda, United States
  • Kaiser Permanene-Oakland
    Verifizierte Postleitzahl
    Oakland, Vereinigte Staaten
  • Children's Hospital of Orange County
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten
  • Lucile Packard Children's Hospital Stanford University
    Verifizierte Postleitzahl
    Palo Alto, Vereinigte Staaten
  • Alfred I duPont Hospital for Children
    Verifizierte Postleitzahl
    Wilmington, Vereinigte Staaten
  • Golisano Children's Hospital of Southwest Florida
    Verifizierte Postleitzahl
    Fort Myers, Vereinigte Staaten
  • University of Florida Health Science Center - Gainesville
    Verifizierte Postleitzahl
    Gainesville, Vereinigte Staaten
  • Nemours Children's Hospital
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten

Häufige Fragen

What is CML?

CML stands for Chronic Myeloid Leukemia, a type of cancer that starts in the blood-forming cells of the bone marrow. 'Philadelphia chromosome-positive' means there's a specific genetic change in the cancer cells.

What is Bosutinib?

Bosutinib is a medicine being studied as a treatment for CML. It's a type of drug called a 'tyrosine kinase inhibitor' (TKI), which works by blocking signals that help cancer cells grow.

What does 'resistant' or 'intolerant' mean?

If your CML is 'resistant,' it means previous treatments haven't worked well enough. If you are 'intolerant,' it means you had severe side effects from previous CML medicines and couldn't continue taking them.

Will I get a placebo (dummy medicine)?

No, this study does not use a placebo. All participants will receive Bosutinib, the study medication.

Wie lange werde ich an der Studie teilnehmen?

The study will involve ongoing treatment and check-ups. The exact duration for you will depend on your response to the treatment and what your doctor advises.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.